Literature DB >> 18827027

Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1.

Lindi Tan1, Phuong Thi Nguyen Sarkis, Tao Wang, Chunjuan Tian, Xiao-Fang Yu.   

Abstract

Human cytidine deaminase apolipoprotein B mRNA-editing catalytic polypeptide-like 3 (APOBEC3) proteins have been classified as either Z1- or Z2-type cytidine deaminases on the basis of phylogenetic analysis of their catalytic domains. Despite the identification of a number of Z1-type domain-containing cytidine deaminases, only one copy of Z2-type cytidine deaminase has been detected in each of the mammalian species evaluated thus far. Z1-type human APOBEC3 proteins are known to exhibit broad activities against diverse retroelements. However, the potential role of the only human Z2-type cytidine deaminase, APOBEC3H (A3H), in the restriction of retroelements has not yet been fully characterized. Here, we demonstrate that human A3H is a potent inhibitor of non-LTR LINE-1 transposition. Interestingly, it was also as efficient as A3G in inhibiting Alu retrotransposition, despite its poor association with Alu RNA. We have further demonstrated, for the first time, that human APOBEC3DE is also a potent inhibitor of Alu retrotransposition. Variants of A3H have divergent antiviral activities against HIV-1-Vif-deficient viruses. Unlike the anti-HIV-1 cytidine deaminases A3G and A3F, A3H is moderately regulated by interferons. These observations suggest that human Z2-type cytidine deaminase A3H variants have varying intrinsic abilities to restrict retroelements and that various APOBEC3 proteins may have evolved distinct inhibitory mechanisms against retroelements.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18827027      PMCID: PMC2626612          DOI: 10.1096/fj.07-088781

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  83 in total

1.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

2.  Comment on "Inhibition of hepatitis B virus replication by APOBEC3G".

Authors:  Christine Rösler; Josef Köck; Michael H Malim; Hubert E Blum; Fritz von Weizsäcker
Journal:  Science       Date:  2004-09-03       Impact factor: 47.728

3.  Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.

Authors:  Andrew Mehle; Joao Goncalves; Mariana Santa-Marta; Mark McPike; Dana Gabuzda
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

4.  APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis.

Authors:  Igor B Rogozin; Malay K Basu; I King Jordan; Youri I Pavlov; Eugene V Koonin
Journal:  Cell Cycle       Date:  2005-09-06       Impact factor: 4.534

5.  Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.

Authors:  Bärbel Schröfelbauer; Tilo Senger; Gerard Manning; Nathaniel R Landau
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  APOBEC3G targets specific virus species.

Authors:  Masayuki Kobayashi; Akifumi Takaori-Kondo; Keisuke Shindo; Aierken Abudu; Keiko Fukunaga; Takashi Uchiyama
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

7.  Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.

Authors:  Eri Miyagi; Sandrine Opi; Hiroaki Takeuchi; Mohammad Khan; Ritu Goila-Gaur; Sandra Kao; Klaus Strebel
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

8.  LINE-mediated retrotransposition of marked Alu sequences.

Authors:  Marie Dewannieux; Cécile Esnault; Thierry Heidmann
Journal:  Nat Genet       Date:  2003-08-03       Impact factor: 38.330

9.  Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses.

Authors:  Cécile Esnault; Jean Millet; Olivier Schwartz; Thierry Heidmann
Journal:  Nucleic Acids Res       Date:  2006-03-14       Impact factor: 16.971

10.  Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.

Authors:  Sara L Sawyer; Michael Emerman; Harmit S Malik
Journal:  PLoS Biol       Date:  2004-07-20       Impact factor: 8.029

View more
  61 in total

1.  Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity.

Authors:  Xiaojun Wang; Aierken Abudu; Sungmo Son; Ying Dang; Patrick J Venta; Yong-Hui Zheng
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.

Authors:  Mawuena Binka; Marcel Ooms; Myeika Steward; Viviana Simon
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

3.  The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.

Authors:  Marcel Ooms; Susan Majdak; Christopher W Seibert; Ariana Harari; Viviana Simon
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

4.  APOBEC3H polymorphisms associated with the susceptibility to HIV-1 infection and AIDS progression in Japanese.

Authors:  Daisuke Sakurai; Yasumasa Iwatani; Hitoshi Ohtani; Taeko K Naruse; Hiroshi Terunuma; Wataru Sugiura; Akinori Kimura
Journal:  Immunogenetics       Date:  2015-02-27       Impact factor: 2.846

Review 5.  Functions and regulation of the APOBEC family of proteins.

Authors:  Harold C Smith; Ryan P Bennett; Ayse Kizilyer; William M McDougall; Kimberly M Prohaska
Journal:  Semin Cell Dev Biol       Date:  2011-10-06       Impact factor: 7.727

6.  N-terminal hemagglutinin tag renders lysine-deficient APOBEC3G resistant to HIV-1 Vif-induced degradation by reduced polyubiquitination.

Authors:  Yudi Wang; Qiujia Shao; Xianghui Yu; Wei Kong; James E K Hildreth; Bindong Liu
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

7.  Polymorphism in human APOBEC3H affects a phenotype dominant for subcellular localization and antiviral activity.

Authors:  Melody M H Li; Michael Emerman
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

Review 8.  Post-transcriptional regulation of LINE-1 retrotransposition by AID/APOBEC and ADAR deaminases.

Authors:  Elisa Orecchini; Loredana Frassinelli; Silvia Galardi; Silvia Anna Ciafrè; Alessandro Michienzi
Journal:  Chromosome Res       Date:  2018-02-02       Impact factor: 5.239

9.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

10.  Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.

Authors:  Eric W Refsland; Mark D Stenglein; Keisuke Shindo; John S Albin; William L Brown; Reuben S Harris
Journal:  Nucleic Acids Res       Date:  2010-03-22       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.